Biogen Idec's CEO Discusses Q3 2011 Results - Earnings Call Transcript Seeking Alpha Additional news this quarter from our late-stage pipeline, including data presented at last week's ECTRIMS meeting for SELECT, the first of 2 registrational trials for daclizumab, which is being evaluated as once monthly or biweekly subcutaneous ... |
